platoseedplatoseed
XGenomes is building the sequencing technology of the future.
At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive "dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables.
XGenomes is developing advanced sequencing technology aimed at enabling multi-omic readouts and precision healthcare. Their approach centers on a compact, multi-omic sequencing platform powered by super-resolution imaging and AI to detect molecular signals of health, disease, and aging.
XGenomes offers a streamlined sequencing solution built around a compact 'One Box' system for sample preparation and sequencing, plus dedicated modules for multi-omic readout and scalable throughput (mid- and high-throughput). The technology uses fluorescent probes to read billions of densely packed molecules at single-molecule, nanometric resolution, with machine learning translating blinking patterns into genetic sequences and epigenetic information. The platform is designed to provide continuous health baselines, monitoring, early disease signals, and tracking intervention effects across an individual’s lifetime.
Who it’s for: Healthcare institutions and providers, genomic research labs, biopharma companies, and precision medicine initiatives seeking affordable, scalable multi-omic sequencing and early-detection capabilities.
Hiring/traction/funding mentions implied by 'careers' and ongoing product development for high-throughput sequencing; company position suggests early-stage to growth in a niche biotech. No explicit funding figures provided.
Discovering the true signals of disease to power life-changing drugs.
The better way to run single cell genomics
